Inspire Medical Systems, Inc. (NYSE: INSP) has announced the departure of its Chief Financial Officer, Rick Buchholz, effective December 31, 2025. Buchholz, who joined the company in 2014, will continue in a financial advisory role through February 28, 2026, to ensure a smooth transition. During his tenure, he played a key role in the company's growth, with revenue increasing from $4 million to over $800 million in 2024.
The company has reaffirmed its previously issued guidance for full-year 2025, with revenue expected to be in the range of $900 to $910 million. Additionally, the gross margin is anticipated to be between 84% and 86%, and diluted net income per share is forecasted to be in the range of $0.40 to $0.50.
Inspire Medical Systems is actively searching for its next Chief Financial Officer as it looks ahead to its next phase of growth.
Inspire Medical Systems focuses on developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea. Its proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology providing a safe and effective treatment for moderate to severe obstructive sleep apnea. Following these announcements, the company's shares moved 0.36%, and are now trading at a price of $92.08. If you want to know more, read the company's complete 8-K report here.
